BAJAJ BROKING
Biocon Biologics’ YESINTEK, a monoclonal antibody for autoimmune diseases, secures US FDA approval. Collaboration with Janssen targets commercialisation by February 2025.
Biocon Biologics has announced the US Food and Drug Administration (FDA) approval of YESINTEK, a monoclonal antibody developed to treat chronic autoimmune diseases. The drug addresses conditions like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. By targeting proteins responsible for inflammation, YESINTEK offers a novel treatment option, advancing care for patients managing these lifelong conditions. The approval reinforces Biocon Biologics’ strategic focus on the US market, potentially influencing the Biocon Biologics share price positively.
Also read: Jet Fuel ATF Prices Surge 1.45% in Delhi, LPG Rates Also Hiked
FDA Approval Date: Announced in 2024.
Target Diseases: Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Collaboration: Partnership with Janssen Biotech, Janssen Sciences Ireland, and Johnson & Johnson.
Market Launch: Targeted by February 22, 2025.
Also read: Hero Future Energies to Invest ₹11,000 Crore in Karnataka’s Green Energy
Aspect | Details |
Approval Date | 2024 |
Commercialisation Target | No later than February 22, 2025 |
Key Collaborators | Janssen Biotech, Johnson & Johnson |
Focus Market | United States |
The licensing agreement with Janssen Biotech, announced earlier this year, paves the way for commercialisation of YESINTEK in the U.S. The collaboration aims to accelerate the drug’s availability, leveraging Janssen’s healthcare expertise.
This approval is a significant milestone for Biocon Biologics, marking its growing footprint in the U.S. healthcare market. The company’s focus on developing and commercialising advanced therapies aligns with its broader objectives of addressing unmet medical needs. The milestone could bolster the Biocon Biologics share price, reflecting investor confidence in the company’s expanding product portfolio.
YESINTEK’s approval brings a promising solution for millions affected by autoimmune disorders. By targeting inflammation-causing proteins, the drug aims to reduce disease symptoms and improve patient outcomes. This achievement underscores Biocon Biologics’ commitment to pioneering solutions in biotechnology.
The US FDA approval of YESINTEK is a pivotal moment for Biocon Biologics, setting the stage for its strengthened presence in the U.S. pharmaceutical market. With strategic partnerships and innovative therapies, the company continues to make strides in addressing critical healthcare challenges.
Also read: Greaves Cotton Approves IPO for Electric Mobility Arm GEML
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading